NOS-mediated morphological and molecular modifications in rats infused with Aβ (1-40), as a model of Alzheimer's disease, in response to a new lipophilic molecular combination codrug-1

Experimental Gerontology

Volumn 46, Issue 4, 2011, Pages 273-281

  Zara, Susi ^a   Di Stefano, Antonio ^a   Nasuti, Cinzia ^b   Rapino, Monica ^c   Patruno, Antonia ^a   Pesce, Mirko ^a   Sozio, Piera ^a   Cerasa, Laura S ^a   Cataldi, Amelia ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

^c Istituto di Genetica Molecolare Del CNR   (Italy)

Author keywords

Alzheimer's disease; Codrug 1; Ibuprofen; Nitric oxide synthases; Rat brain

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; CODRUG 1; IBUPROFEN; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DRUG EFFECT; MALE; MEMORY DISORDER; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; VASODILATATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; BEHAVIOR, ANIMAL; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; HUMANS; IBUPROFEN; MALE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR;

RATTUS;

EID: 79952700410     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exger.2010.11.001     Document Type: Article

References (55)

1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S.T., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 3:383-421.
2. Asahina M., Yoshiyama Y., Hattori T. Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin. Neuropathol. 2001, 20:60-63.
3. Atochina-Vasserman E.N., Beers M.F., Kadire H., Tomer Y., Inch A., Scott P., Guo C.J., Gow A.J. Selective inhibition of inducible NO synthase activity in vivo reverses inflammatory abnormalities in surfactant protein D-deficient mice. J. Immunol. 2007, 179:8090-8097.
4. Bateman D.A., McLaurin J.A., Chakrabartty A. Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding. BMC Neurosci. 2007, 8:29-34.
5. Caughey B., Lansbury P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 2003, 26:267-298.
6. Chung K.K., David K.K. Emerging roles of nitric oxide in neurodegeneration. Nitric Oxide 2010, 22:290-295.
7. Chung H.T., Pae H.O., Choi B.M., Billiar T.R., Kim Y.M. Nitric Oxide as a bioregulator of apoptosis. Biochem. Biophys. Res. Commun. 2001, 282:1075-1079.
8. Colton C.A., Wilcock D.M., Wink D.A., Davis J., Van Nostrand W.E., Vitek M.P. The effects of NOS2 gene deletion on mice expressing mutated human Abeta PP. J. Alzheimers Dis. 2008, 15:571-587.
9. Czapski G.A., Cakala M., Chalimoniuk M., Gajkowska B., Strosznajder J.B. Role of nitric oxide in the brain during lipopolysaccharide-evoked systemic inflammation. J. Neurosci. Res. 2007, 85:1694-1703.
10. Davis K.L. NSAID and Alzheimer's disease: possible answers and new questions. Mol. Psychiatry 2002, 7:925-926.
11. Di Stefano A., Sozio P., Cerasa L.S., Iannitelli A., Cataldi A., Zara S., Giorgioni G., Nasuti C. Ibuprofen and lipoic acid diamides as codrugs with neuroprotective activity: pharmacological properties and effects in beta-amyloid-protein (1-40) infused Alzheimer's disease rat model. Int. J. Immunopathol. Pharmacol. 2010, 23:589-599.
12. Drouet B., Pincon-Raymond M., Chambaz J., Pillot T. Molecular basis of Alzheimer's disease. Cell. Mol. Life Sci. 2000, 57:705-715.
13. Fialkow L., Wang Y., Downey G.P. Reactive oxygen and nitrogen species as signalling molecules regulating neutrophil function. Free Radic. Biol. Med. 2007, 42:153-164.
14. Fujisawa H., Fujiwara T., Takeuchi Y., Omata K. Synthesis and optical resolution of 2-aryl-2-fluoropropionic acids, fluorinated analogues of non-steroidal anti-inflammatory drugs (NSAIDs). Chem. Pharm. Bull. 2005, 53:524-548.
15. Gow A.J., Ischiropoulos H. Nitric oxide chemistry and cellular signalling. J. Cell. Physiol. 2001, 187:277-282.
16. Hevel J.M., Marletta M.A. Nitric oxide synthase assays. Meth. Enzymol. 1994, 133:250-258.
17. Hirohata M., Ono K., Naiki H., Yamada M. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Neuropharmacology 2005, 49:1088-1099.
18. Jan A., Gokce O., Luthi-Carter R., Lashuel H.A. The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. J. Biol. Chem. 2008, 283:28176-28189.
19. Lahiri D.K., Chen D., Ge Y.W., Farlow M., Kotwal G., Kanthasamy A., Ingram D.K., Greig N.H. Does nitric oxide synthase contribute to the pathogenesis of Alzheimer's disease? Effects of β amyloid deposition on NOS in transgenic mouse brain with AD pathology. Ann. NY Acad. Sci. 2003, 1010:639-642.
20. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 1998, 95:6448-6453.
21. Leslie R.A. Imaging Alzheimer's disease in vivo: not so implaque-able anymore. Trends Neurosci. 2002, 25:232-233.
22. Leuchtenberger S., Beher D., Weggen S. Selective modulation of Abeta-42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond. Curr. Pharm. Des. 2006, 12:4337-4355.
23. Limon I.D., Diaz A., Mendieta L., Chamorro G., Espinos B., Zenteno E., Guevara J. Amyloid-β (25-35) impairs memory and increases NO in the temporal cortex of rats. Neurosci. Res. 2009, 63:129-137.
24. Lüth H.J., Holzer M., Gärtner U., Staufenbiel M., Arendt T. Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology. Brain Res. 2001, 14:57-67.
25. Mackenzie I.R. Anti-inflammatory drugs and Alzheimer-type pathology in aging. Neurology 2000, 54:732-734.
26. Malinski T. Nitric oxide and nitrosative stress in Alzheimer's disease. J. Alzheimers Dis. 2007, 11:207-218.
27. McCann S.M. The nitric oxide hypothesis of aging. Exp. Gerontol. 1998, 33:813-826.
28. Miguel-Hidalgo J.J., Cacabelos R. β-Amyloid (1-40)-induced neurodegeneration in the rat hippocampal neurons of the CA1 subfield. Acta Neuropathol. 1998, 95:455-465.
29. Miners J.S., Baig S., Palmer J., Palmer L.E., Kehoe P.G., Love S. Aβ-Degrading enzymes in Alzheimer's disease. Brain Pathol. 2008, 18:240-252.
30. Moncada S., Bolanos J.P. Nitric oxide, cell bioenergetics and neurodegeneration. J. Neurochem. 2006, 97:1676-1689.
31. Multhaup G., Ruppert T., Schlicksupp A., Hesse L., Beher D., Masters C.L., Beyreuther K. Reactive oxygen species and Alzheimer's disease. Biochem. Pharmacol. 1997, 54:533-539.
32. Nag E., Yee B.K., Tang F. Reduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of β-amyloid (1-40). Brain Res. Bull. 1999, 50:251-262.
33. Packer L., Tritschler H.J., Wessel K. Neuroprotection by the metabolic antioxidant β lipoic acid. Free Radic. Biol. Med. 1997, 22:359-378.
34. Parihar M.S., Hemmani T. Alzheimer's disease pathogenesis and therapeutic interventions. J. Clin. Neurosci. 2004, 11:456-467.
35. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1997, Academic Press, North Ryde, Sydney, Australia. Ed. 2.
36. Pepicelli O., Raiteri M., Fedele E. The NOS/sGC pathway in the rat central nervous system: a microdialysis overview. Neurochem. Int. 2004, 45:787-797.
37. Pignatello R., Guccione S., Castelli F., Sampietro M.G., Giurato L., Lombardo M., Pugliesi G., Toth I. Enhancement of drug affinity for cell membranes by conjugation with lipoaminoacids: II. Experimental and computational evidence using biomembrane models. Int. J. Pharm. 2006, 310:53-63.
38. Pignatello R., Pantò V., Salmaso S., Bersani S., Ristarà V., Kepe V., Barrio J.R., Pugliesi G. Flurbiprofen derivatives in Alzheimer's disease: synthesis, pharmacokinetic and biological assessment of lipoamino acid prodrugs. Bioconjug. Chem. 2008, 19:349-357.
39. Reljanovic M., Reichel G., Rett k., Lobisch M., Schuette K., Moller W., Tritschler H.J., Mehnert H. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (β-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radic. Res. 1999, 31:171-179.
40. Rich J.B., Rasmusson D.X., Folstein M.F., Carson K.A., Kawas C., Brandt J. Non steroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995, 45:51-55.
41. Shaul P.W. Regulation of endothelial nitric oxide synthase: location, location, location. Annu. Rev. Physiol. 2002, 64:749-774.
42. Smith M.A., Perry G., Richey P.L., Sayre L.M., Anderson V.E., Beal M.F., Kowall N. Oxidative damage in Alzheimer's. Nature 1996, 382:120-121.
43. Sozio P., D'Aurizio E., Iannitelli A., Cataldi A., Zara S., Cantalamessa F., Nasuti C., Di Stefano A. Ibuprofen and lipoic acid diamides as potential codrugs with neuroprotective activity. Arch. Pharm. (Weinheim) 2010, 343:133-142.
44. Stepanichev M., Zdobnova I., Zarubenko I., Lazareva N., Gulyaeva N.V. Differential effects of tumor necrosis factor-alpha co-administered with amyloid beta-peptide (25-35) on memory function and hippocampal damage in rat. Behav. Brain Res. 2006, 175:352-361.
45. Stepanichev M.Y., Onufriev M.V., Yakovlev A.A., Khrenov A.I., Peregud D.T., Vorontsova O.N., Lazareva N.A., Gulyaeva N.V. Amyloid-β (25-35) increases activity of neuronal NO-synthase in rat brain. Neurochem. Int. 2008, 52:1114-1124.
46. Suzuki N., Urano J., Tamanoi F. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc. Natl Acad. Sci. USA 1998, 95:15356-15361.
47. Torreilles J. Nitric oxide: one of the more conserved and widespread signalling molecules. Front. Biosci. 2001, 6:D1161-D1172.
48. Torreilles F., Touchan J. Pathogenic theories and intrathecal analysis of the sporadic form of Alzheimer's disease. Prog. Neurobiol. 2002, 66:191-203.
49. Vajda F.J.E. Neuroprotection and neurodegenerative disease. J. Clin. Neurosci. 2002, 9:4-8.
50. Vlad S.C., Miller D.R., Kowall N.W., Felson D.T. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008, 70:1672-1677.
51. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
52. Wang R., Zhang H.Y., Tang X.C. Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid-protein (1-40) in rat. Eur. J. Pharmacol. 2001, 421:149-156.
53. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., Findlay K.A., Smith T.E., Murphy M.P., Bulter T., Kang D.E., Marquez-Sterlingk N., Golde T.E., Koo E.H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001, 414:212-216.
54. Zetterberg H., Blennow K., Hanse E. Amyloid β and APP as biomarkers for Alzheimer's disease. Exp. Gerontol. 2010, 45:23-29.
55. Zhu X., Smith M.A., Honda K., Aliev G., Moreira P.I., Nunomura A., Casadesus G., Harris P.L., Siedlak S.L., Perry G. Vascular oxidative stress in Alzheimer's disease. J. Neurol. Sci. 2007, 257:240-246.